Cisplatin Exposure and Tumor Response
Author Information
Author(s): JHM Schellens, J Mal, ASTh Planting, MEL van der Burg, E van Meerten, M de Boer-Dennert, PIM Schmitz, G Stoter, J Verweij
Primary Institution: Rotterdam Cancer Institute (Daniel den Hoed Kliniek)
Hypothesis
The likelihood of a tumor response in potentially sensitive tumors and interindividual variation in the formation of DNA-adducts in WBC are dominated by interpatient differences in the magnitude of exposure to active, i.e., non-protein bound, cisplatin.
Conclusion
The study found that individualised dosing of cisplatin based on AUC or DNA-adduct levels could lead to increased response rates in patients with solid tumors.
Supporting Evidence
- The AUC was highly variable with a mean of 2.48 and a standard deviation of 0.51.
- There were 20 responders and 25 non-responders among the 45 evaluable patients.
- The AUC, AUA, and A1h were significantly higher in responders than in non-responders (P<0.0001).
- Logistic regression analysis showed AUC, AUA, and A1h were important predictors of response.
- Individualized dosing of cisplatin using AUC or DNA-adducts should lead to increased response rates.
Takeaway
This study shows that how much cisplatin a patient gets can change how well it works, so doctors should give the right amount for each person to help them get better.
Methodology
Patients were treated with six weekly courses of cisplatin, and DNA-adduct levels were measured in WBC at various time points to assess the relationship with tumor response.
Limitations
The study had a small sample size and included a heterogeneous population with various tumor types.
Participant Demographics
Patients aged 18-75 with pathologically confirmed cancer not curable by surgery, radiotherapy, or chemotherapy.
Statistical Information
P-Value
< 0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website